|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we demonstrated that the treatment with YS110 induced nuclear translocation of both cell-surface CD26 and YS110 in cancer cells and xenografted tumor.
|
23638030 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High DPP4 expression was associated with extrathyroidal extension (P < 0.001), BRAF mutation (P < 0.001), and advanced tumor stage (P = 0.007) in papillary thyroid cancer.
|
28575350 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that quantification of CD26- T-cells reflects the tumor cell amount more accurate and should be preferred in the clinical setting.
|
18672285 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings that CD26 expression can be an in vivo marker of tumor sensitivity to doxorubicin treatment may lead to future treatment strategies targeting CD26/DPPIV for selected human cancers in the clinical setting.
|
15753397 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this paper, we will review emerging data that suggest CD26 may be an appropriate therapeutic target for the treatment of selected neoplasms and immune disorders.
|
17346218 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD26 is a M(r) 110,000 surface glycoprotein with diverse functional properties, including having a potentially significant role in tumor development, and antibodies to CD26 mediate pleomorphic cellular functions.
|
11448921 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL.
|
19247978 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These cells reside within the CD34<sup>+</sup> /CD38<sup>─</sup> /Lin<sup>─</sup> fraction and score positive for CD26 (dipeptidylpeptidase IV) a marker, expressed in both bone marrow (BM) and peripheral blood (PB) samples, that discriminates CML cells from normal hematopoietic stem cells (HSCs) or from LSCs of other myeloid neoplasms.
|
30714299 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We hypothesized that this subpopulation of cancer stem cells arises in the late stage of carcinogenesis from the bulk of tumor daughter cells which are CD26-.
|
28545226 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo experiments with mouse xenograft models involving human malignant mesothelioma cells show that humanized anti-CD26 mAb treatment drastically inhibits tumor growth in tumor-bearing mice, resulting in enhanced survival.
|
17634548 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previously we have demonstrated that DPPIV abrogates growth factor independence and functions as a tumor suppressor gene in melanomas.
|
17981724 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings hence suggest that CD26 plays an important role in tumor development and may be a novel therapeutic target for selected neoplasms.
|
16061680 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the syngeneic 4T1 metastatic breast cancer model, DPP4 overexpression increased tumour development, whereas treatment with sitagliptin and/or juglone suppressed it.
|
26267432 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis.
|
31398954 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, in patients without distant metastasis at the time of presentation, the presence of CD26(+) cells in their primary tumors predicted distant metastasis on follow-up.
|
20569697 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pharmacological blockade of CD26, via Sitagliptin, reduced growth of InvEE tumours, while combined inhibition of IL-1α and CD26 delayed tumour onset and reduced tumour incidence.
|
21765471 |
2012 |